ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2014
History, genetics, and strategies for cancer prevention in Lynch syndrome.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 84 citations in OpenAlex.
- Barriers and facilitators of adherence to cancer prevention in Lynch Syndrome: an integrative review.Hereditary cancer in clinical practice · 2026Review
- Emerging Molecular Insights and Targeted Therapeutics in Colorectal Cancer: From Emerging Approaches to Personalized Medicine.Journal of gastrointestinal cancer · 2026Review
- From theory to practice: improving Lynch syndrome recognition through evidence-based education.Familial cancer · 2026Review
- Metachronous triple primary malignancies: a case report of NGS-guided multidisciplinary management and literature review.Frontiers in oncology · 2026Review
- Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Frontiers in immunology · 2026Review
- A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.Oncology reviews · 2025Review
- Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers.International journal of clinical oncology · 2024Article
- Pancreatic Cancer: A Review of Risk Factors.Life (Basel, Switzerland) · 2024Review
- Early-Onset/Young-Onset Colorectal Carcinoma: A Comparative Analysis of Morphological Features and Biomarker Profile.Cureus · 2023Article
- Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation.Frontiers in genetics · 2022Article
- Rad5 and Its Human Homologs, HLTF and SHPRH, Are Novel Interactors of Mismatch Repair.Frontiers in cell and developmental biology · 2022Article
- Lynch Syndrome-Associated Endometrial Cancer With Combined EPCAM-MSH2 Deletion: A Case Report.Frontiers in oncology · 2022Review
- Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease.Molecular and clinical oncology · 2021Article
- Classification and genetic counselling for a novel splicing mutation of theGastroenterology report · 2021Article
- Clinical challenges in interpreting multiple pathogenic mutations in single patients.Hereditary cancer in clinical practice · 2021Article
- Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia.Epigenomics · 2020Article
- Diagnostics of Mutations in MMR/Diagnostics (Basel, Switzerland) · 2020Review
- Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?Cancer metastasis reviews · 2020Review
- A Novel GermlineGenes · 2020Article
- Chromatin remodeling and mismatch repair: Access and excision.DNA repair · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is the most common gastrointestinal malignancy and the third cause of cancer death in men and women in the United States. The majority of CRC cases diagnosed annually are due to sporadic events, but up to 6% are attributed to known monogenic disorders that confer a markedly increased risk for the development of CRC and multiple extracolonic malignancies. Lynch syndrome is the most common inherited CRC syndrome and is associated with mutations in DNA mismatch repair genes, mainly MLH1 and MSH2 but also MSH6, PMS2, and EPCAM. Although the risk of CRC and endometrial cancer may approach near 75% and 50%, respectively, in gene mutation carriers, the identification of these individuals and at-risk family members through predictive genetic testing provides opportunities for cancer prevention including specialized cancer screening, intensified surveillance, and/or prophylactic surgeries. This article will provide a review of the major advances in risk assessment, molecular genetics, DNA mutational analyses, and cancer prevention and management made since Lynch syndrome was first described 100 years ago.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.